Abstract
A well-defined pathway for the accelerated development and approval of targeted cancer therapies and companion diagnostics would reduce uncertainty, improve efficiency in development and provide an effective incentive for developers.
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / chemistry
-
Clinical Trials as Topic / trends
-
Drug Delivery Systems / trends*
-
Drug Discovery / trends*
-
Humans
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Time Factors